[{"id":"f5563541-42ba-4928-8bc5-ee322d350ebf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199030","created_at":"2021-09-05T08:53:21.634Z","updated_at":"2024-07-02T16:35:52.983Z","phase":"Phase 2","brief_title":"Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath","source_id_and_acronym":"NCT00199030","lead_sponsor":"Goethe University","biomarkers":" CD52","pipe":" | ","alterations":" CD52 expression","tags":["CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • cladribine"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 02/01/2004","start_date":" 02/01/2004","primary_txt":" Primary completion: 04/01/2008","primary_completion_date":" 04/01/2008","study_txt":" Completion: 04/01/2008","study_completion_date":" 04/01/2008","last_update_posted":"2023-03-20"},{"id":"bd3cf553-3d2b-4a93-894b-9b071c94adb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00069238","created_at":"2021-01-18T00:10:21.560Z","updated_at":"2024-07-02T16:36:16.637Z","phase":"Phase 2","brief_title":"Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas","source_id_and_acronym":"NCT00069238","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • CD52","pipe":" | ","alterations":" ALK positive • CD52 expression","tags":["ALK • CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Campath (alemtuzumab) • vincristine • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/19/2003","start_date":" 09/19/2003","primary_txt":" Primary completion: 06/11/2009","primary_completion_date":" 06/11/2009","study_txt":" Completion: 03/17/2021","study_completion_date":" 03/17/2021","last_update_posted":"2022-02-24"},{"id":"4878c545-1abc-40e1-850b-d27be0d5f377","acronym":"ACT-1","url":"https://clinicaltrials.gov/study/NCT00646854","created_at":"2021-01-18T02:24:24.264Z","updated_at":"2024-07-02T16:37:02.320Z","phase":"Phase 3","brief_title":"Alemtuzumab and CHOP in T-cell Lymphoma","source_id_and_acronym":"NCT00646854 - ACT-1","lead_sponsor":"Aarhus University Hospital","biomarkers":" CD34 • CD52","pipe":" | ","alterations":" CD34 positive • CD52 expression","tags":["CD34 • CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive • CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Campath (alemtuzumab) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2019-03-01"},{"id":"d341898e-c40c-45c0-978e-227bf3b840f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00935792","created_at":"2021-01-18T03:37:37.975Z","updated_at":"2024-07-02T16:37:17.541Z","phase":"Phase 1/2","brief_title":"Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT00935792","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD5 • CD52 • FCER2","pipe":" | ","alterations":" CD20 expression • CD52 expression","tags":["CD20 • CCND1 • CD5 • CD52 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Campath (alemtuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-09-26"}]